By Admin at 13 Apr 2016

Patients with acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma and chronic lymphocytic leukemia are taking part in the trial and received an experimental “living” immunotherapy. The results have so far been “extraordinary,” according to the researchers, including among some patients that were initially given only months to live.